Amgen Bests Regeneron in Patent Fight Over Cholesterol Drugs
This article is for subscribers only.
Amgen Inc. won a legal victory over Regeneron Pharmaceuticals Inc. in an intellectual property battle over their cholesterol-reducing drugs. Regeneron said it would appeal the decision.
A federal jury in Wilmington, Delaware, rejected Regeneron’s challenges and ruled in Amgen’s favor that two of its patents on its drug, Repatha, were valid, according to a statement Wednesday from Regeneron and its partner Sanofi. Amgen rose less than 1 percent to $143.97 at 3:32 p.m. in New York. Regeneron rose less than 1 percent to $369.04.